Overall, we here successfully demonstrate the efficacy of the combined treatment modality of radiotherapy with the novel ADAM17-directed inhibitory antibody MEDI3622 for lung adenocarcinoma. The gene discussed is ADAM17; the disease is lung adenocarcinoma.